(Q44452204)

3 December 2017

title

Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension (English)

1 reference

3 December 2017

S G Chrysant

1

1 reference

3 December 2017

T C Marbury

series ordinal

2

1 reference

3 December 2017

T D Robinson

series ordinal

3

1 reference

3 December 2017

publication date

1 June 2003

1 reference

Journal of Human Hypertension

3 December 2017

published in

1 reference

3 December 2017

volume

17

1 reference

3 December 2017

issue

6

1 reference

3 December 2017

page(s)

425-432

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.jhh.1001577

3 December 2017

exact match

0 references

cites work

Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001577

Safety and efficacy of angiotensin II receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001577

Clinical studies of CS-866, the newest angiotensin II receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001577

Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001577

Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001577

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001577

21 January 2018

The safety of amlodipine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001577

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001577

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001577

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001577

Continuation of initial antihypertensive medication after 1 year of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001577

Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001577

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001577

Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001577

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001577

Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001577

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001577

The prevention or delay of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001577

7 January 2021

Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001577

7 January 2021

Isolated systolic hypertension in the elderly: survey of practitioners' attitude and management

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001577

7 January 2021

A dose-response study of amlodipine in mild to moderate hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001577

7 January 2021

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001577

7 January 2021

Identifiers

DOI

10.1038/SJ.JHH.1001577

1 reference

3 December 2017

1 reference